We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Gene Therapy for X-linked Chronic Granulomatous Disease (CGD) in Children (XCGDinChildren)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00927134
First Posted: June 24, 2009
Last Update Posted: September 27, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Goethe University
Information provided by (Responsible Party):
University of Zurich
  Purpose
The aim of the study is to evaluate the side effects and risks after infusion of retroviral gene corrected autologous CD34+ cells of the peripheral blood of chemotherapy conditioned (busulphan) children with chronic granulomatous disease (CGD). Also gene corrected and functional active granulocytes in the peripheral blood and the engraftment in the bone marrow of the patients will be monitored an documented.

Condition Intervention Phase
Chronic Granulomatous Disease Genetic: retroviral SF71-gp91phox transduced CD34+ cells Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I/II Gene Therapy Study for X-linked Chronic Granulomatous Disease in Children

Resource links provided by NLM:


Further study details as provided by University of Zurich:

Primary Outcome Measures:
  • eradication of pre-existing therapy refractory bacterial and/or fungal infections [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • Reconstitution of ROS production by peripheral blood cells [ Time Frame: 1 month ]

Enrollment: 2
Study Start Date: June 2004
Study Completion Date: September 2011
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Genetic: retroviral SF71-gp91phox transduced CD34+ cells
    autologous ex-vivo transduced (SF71-gp91phox)CD34+ cells
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   1 Year to 18 Years   (Child, Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • x-linked Chronic Granulomatous Disease
  • history of life-threatening severe infections
  • no HLA-matched related or unrelated donor
  • therapy resistent life threatening infections/organ dysfunction
  • no other treatment options e.g. HSCT

Exclusion Criteria:

  • > 18 years of age
  • HIV infection
  • life expectancy > 2 years
  • infections treatable by conventional therapy (antibiotics, antimycotics, allogeneic granulocytes)
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00927134


Locations
Switzerland
University Children's Hospital
Zürich, Switzerland, CH-8032
Sponsors and Collaborators
University of Zurich
Goethe University
Investigators
Principal Investigator: Reinhard Seger, Prof Dr med University Children's Hospital Zürich
Study Chair: Janine Reichenbach, PD Dr med University Children's Hospital Zürich
Study Chair: Ulrich Siler, Dr rer nat University Children's Hospital Zürich
Study Chair: Manuel Grez, Dr rer nat Georg Speyer Research Institute, Frankfurt a.M.
  More Information

Publications:
Responsible Party: University of Zurich
ClinicalTrials.gov Identifier: NCT00927134     History of Changes
Other Study ID Numbers: PedsZürich_GT05
First Submitted: June 22, 2009
First Posted: June 24, 2009
Last Update Posted: September 27, 2011
Last Verified: September 2011

Keywords provided by University of Zurich:
Chronic Granulomatous Disease in children (=or< 18 years)

Additional relevant MeSH terms:
Granuloma
Granulomatous Disease, Chronic
Lymphoproliferative Disorders
Lymphatic Diseases
Pathologic Processes
Phagocyte Bactericidal Dysfunction
Leukocyte Disorders
Hematologic Diseases
Genetic Diseases, X-Linked
Genetic Diseases, Inborn
Immunologic Deficiency Syndromes
Immune System Diseases